How I treat pediatric venous thromboembolism in the DOAC era
© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
ABSTRACT: The direct oral anticoagulants (DOACs) rivaroxaban and dabigatran are newly licensed for the treatment and prevention of venous thromboembolism (VTE) in children and mark a renaissance in pediatric anticoagulation management. They provide a convenient option over standard-of-care anticoagulants (heparins, fondaparinux, and vitamin K antagonists) because of their oral route of administration, child-friendly formulations, and significant reduction in monitoring. However, limitations related to therapeutic monitoring when needed and the lack of approved reversal agents for DOACs in children raise some safety concerns. There is accumulating experience of safety and efficacy of DOACs in adults for a broad scope of indications; however, the cumulative experience of using DOACs in pediatrics, specifically for those with coexisting chronic illnesses, is sparse. Consequently, clinicians must often rely on their experience for treating VTE and extrapolate from data in adults while using DOACs in children. In this article, the authors share their experience of managing 4 scenarios that hematologists are likely to encounter in their day-to-day practice. Topics addressed include (1) appropriateness of indication; (2) use for special populations of children; (3) considerations for laboratory monitoring; (4) transition between anticoagulants; (5) major drug interactions; (6) perioperative management; and (7) anticoagulation reversal.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
---|---|
Enthalten in: |
Blood - 143(2024), 5 vom: 01. Feb., Seite 389-403 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bhat, Rukhmi V [VerfasserIn] |
---|
Links: |
---|
Themen: |
9NDF7JZ4M3 |
---|
Anmerkungen: |
Date Completed 02.02.2024 Date Revised 24.03.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1182/blood.2022018966 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM358915619 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM358915619 | ||
003 | DE-627 | ||
005 | 20240324234742.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1182/blood.2022018966 |2 doi | |
028 | 5 | 2 | |a pubmed24n1344.xml |
035 | |a (DE-627)NLM358915619 | ||
035 | |a (NLM)37390311 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bhat, Rukhmi V |e verfasserin |4 aut | |
245 | 1 | 0 | |a How I treat pediatric venous thromboembolism in the DOAC era |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.02.2024 | ||
500 | |a Date Revised 24.03.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
520 | |a ABSTRACT: The direct oral anticoagulants (DOACs) rivaroxaban and dabigatran are newly licensed for the treatment and prevention of venous thromboembolism (VTE) in children and mark a renaissance in pediatric anticoagulation management. They provide a convenient option over standard-of-care anticoagulants (heparins, fondaparinux, and vitamin K antagonists) because of their oral route of administration, child-friendly formulations, and significant reduction in monitoring. However, limitations related to therapeutic monitoring when needed and the lack of approved reversal agents for DOACs in children raise some safety concerns. There is accumulating experience of safety and efficacy of DOACs in adults for a broad scope of indications; however, the cumulative experience of using DOACs in pediatrics, specifically for those with coexisting chronic illnesses, is sparse. Consequently, clinicians must often rely on their experience for treating VTE and extrapolate from data in adults while using DOACs in children. In this article, the authors share their experience of managing 4 scenarios that hematologists are likely to encounter in their day-to-day practice. Topics addressed include (1) appropriateness of indication; (2) use for special populations of children; (3) considerations for laboratory monitoring; (4) transition between anticoagulants; (5) major drug interactions; (6) perioperative management; and (7) anticoagulation reversal | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Anticoagulants |2 NLM | |
650 | 7 | |a Dabigatran |2 NLM | |
650 | 7 | |a I0VM4M70GC |2 NLM | |
650 | 7 | |a Rivaroxaban |2 NLM | |
650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
700 | 1 | |a Young, Guy |e verfasserin |4 aut | |
700 | 1 | |a Sharathkumar, Anjali A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 143(2024), 5 vom: 01. Feb., Seite 389-403 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
773 | 1 | 8 | |g volume:143 |g year:2024 |g number:5 |g day:01 |g month:02 |g pages:389-403 |
856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2022018966 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 143 |j 2024 |e 5 |b 01 |c 02 |h 389-403 |